应用肝脏硬度检测联合多普勒超声检测门静脉血流动力学指标评估慢性乙型肝炎患者肝纤维化效能研究*

doi:10.3969/j.issn.1672-5069.2023.04.007

摘要/Abstract

摘要： 目的研究应用瞬时弹性成像技术行肝脏硬度检测(LSM)联合多普勒超声检测门静脉血流动力学指标评估慢性乙型肝炎(CHB)患者肝纤维化程度的效能。方法 2018年12月～2022年10月我院收治的96例CHB患者和同期74例健康体检者,接受FibroTouch检测,获得LSM,和超声检测门静脉主干内径(PVD)、最大流速(Vmax)和平均流速(Vmean),CHB患者接受肝活检。绘制受试者工作特征曲线(ROC)评价指标诊断显著性肝纤维化的效能。结果 CHB组LSM、PVD、Vmax和Vmean分别为(9.5±1.6) kPa、(12.7±2.1) mm、(35.4±3.1)cm/s和(29.8±2.8) cm/s,显著大于健康人【分别为(4.4±0.5)kPa、(10.7±1.6)mm、(26.1±2.5)cm/s和(21.7±2.2)cm/s,P<0.05】;经肝组织病理学检查,在96例CHB患者中,发现非显著性肝纤维化32例,显著性肝纤维化64例;显著性肝纤维化患者LSM和PVD分别为(14.5±2.6)kPa和(13.3±2.3) mm,显著大于非显著性肝纤维化患者【分别为(5.8±0.8)kPa和(11.2±1.8)mm,P<0.05】,而Vmax和Vmean分别为(29.1±2.6)cm/s和(24.2±1.9)cm/s,显著低于非显著性肝纤维化患者【分别为(36.9±3.8)cm/s和(30.6±2.7)cm/s,P<0.05】;经ROC曲线分析显示,分别以LSM为9.5 kPa和PVD为12.0 mm为截断点,两者联合诊断显著性肝纤维化的敏感度为90.1％,特异度为77.4％,显著优于两指标单独检测诊断(P<0.05)。结论使用FibroTouch检测的LSM联合超声检测的PVD诊断CHB患者显著性肝纤维化具有较高的效能,值得临床进一步验证。

关键词: 慢性乙型肝炎, 肝纤维化, 肝硬度检测, 门静脉主干内径, 诊断

Abstract: Objective The aim of this study was to explore the evaluation of liver fibrosis by liver stiffness measurement (LSM) and portal vein hemodynamic index combination in patients with chronic hepatitis B (CHB). Methods A total of 96 patients with CHB confirmed by liver biopsy and 74 healthy individuals were enrolled in our hospital between December 2018 and October 2022, the LSM was detected by FibroTouch scan and the portal vein diameter (PVD), maximum flow velocity (Vmax) and average flow velocity (Vmean) of portal veins were detected by ultrasonography. The diagnostic performance was evaluated by the receiver operating characteristic (ROC) curves. Results The LSM, PVD, Vmax and Vmean in patients with CHB were (9.5±1.6) kPa,(12.7±2.1) mm,(35.4±3.1)cm/s and (29.8±2.8) cm/s, all significantly greater than [(4.4±0.5)kPa, (10.7±1.6)mm,(26.1±2.5)cm/s and (21.7±2.2)cm/s, respectively, P<0.05] in healthy persons; the liver histopathological examination showed non-significant liver fibrosis in 32 cases and significant liver fibrosis in 64 cases in our series; the LSM and the PVD in patients with significant liver fibrosis were (14.5±2.6)kPa and (13.3±2.3) mm, both significantly greater than [(5.8±0.8)kPa and (11.2±1.8)mm, respectively, P<0.05], while the Vmax and Vmean of portal vein blood flow were (29.1±2.6)cm/s and (24.2±1.9)cm/s, both significantly slower than [(36.9±3.8)cm/s and (30.6±2.7)cm/s, respectively, P<0.05] in those without significant liver fibrosis; the ROC analysis showed that the diagnostic efficacy was superior to LSM or PVD alone prediction, with the sensitivity of 90.1％ and the specificity of 77.4%, when the two parameters were combined to assess the significant liver fibrosis in patients with CHB, with the LSM equal to 9.5 kPa and the PVD equal to 12.0 mm as the cut-off-value(P<0.05). Conclusion The validation of combination of LSM by FibroTouch and PVD by ultrasonography in assessing significant liver fibrosis in patients with CHB might be helpful in clinical practice.

Key words: Hepatitis B, Liver fibrosis, Liver stiffness measurement, Portal vein hemodynamic index, Diagnosis

周克丽, 吕晓丽, 周洋, 龙浩成. 应用肝脏硬度检测联合多普勒超声检测门静脉血流动力学指标评估慢性乙型肝炎患者肝纤维化效能研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 480-483.

Zhou Keli, Lyu Xiaoli, Zhou Yang, et al. Concordance between liver biopsy,and the liver stiffness measurement and hemodynamic index combination for the diagnosis of hepatic fibrosis in patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2023, 26(4): 480-483.

参考文献

[1] Inoue T, Kusumoto S, Iio E,et al. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol,2021 ,75(2):302-310.
[2] Bruno S, Pasquino C, Herrera Sanchez MB,et al. HLSC-derived extracellular vesicles attenuate liver fibrosis and inflammation in a murine model of non-alcoholic steatohepatitis. Mol Ther,2020,28(2):479-489.
[3] Tosun M, Uslu H. Comparison of superb microvascular imaging and shear wave elastography for assessing liver fibrosis in chronic hepatitis B. Ultrasonography,2022 ,41(2):394-402.
[4] Trépo C, Chan HL, Lok A.Trépo C, et al.Hepatitis B virus infection. Lancet, 2014,384(9959):2053-2063.
[5] Peng X, Tian A, Li J,et al. Diagnostic value of fibrotouch and non-invasive fibrosis indexes in hepatic fibrosis with different aetiologies. Dig Dis Sci,2022 ,67(6):2627-2636.
[6] Yamamoto A, Ito K, Yasokawa K,,et al. Morphologic changes in hepatitis virus-related liver cirrhosis: Relationship to hemodynamics of portal vein on dynamic contrast-enhanced CT. Radiography (Lond),2021,27(2):598-604.
[7] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版).中华内科杂志,2011,50(2):168-179.
[8] 安红杰, 耿华, 葛志胜,等. 瞬时弹性成像技术在慢性乙型肝炎肝纤维化诊断及预后评估中的价值. 中华医院感染学杂志, 2020,30(22):3443-3447.
[9] Zhou JY, Song LW, Yuan R,et al. Prediction of hepatic inflammation in chronic hepatitis B patients with a random forest-backward feature elimination algorithm. World J Gastroenterol,2021,27(21):2910-2920.
[10] Pokora-Rodak A, Krzowska-Firych J, Tomasiewicz K,et al. Concentration of LDLR, degree of hepatic fibrosis and hepatic steatosis in patients with chronic hepatitis B infection treated with tenofovir disoproxil fumarate. Ann Agric Environ Med,2021,28(3):458-462.
[11] Suarez-Quintero CY, Patarroyo Henao O, Muñoz-Velandia O,et al. Concordance between hepatic biopsy and the APRI index (Ast to Platelet Ratio Index) for the diagnosis of cirrhosis in patients with autoimmune liver disease. Gastroenterol Hepatol,2021 ,44(7):465-471.
[12] Li J, Qureshi M, Gupta A,et al. Quantification of degree of liver fibrosis using fibrosis area fraction based on statistical chi-square analysis of heterogeneity of liver tissue texture on routine ultrasound images. Acad Radiol,2019 ,26(8):1001-1007.
[13] Qu Y, Song YY, Chen CW,et al. Diagnostic performance of FibroTouch ultrasound attenuation parameter and liver stiffness measurement in assessing hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Clin Transl Gastroenterol,2021 ,12(4):e00323.
[14] Zuo Z, Cui H, Wang M,et al. Diagnostic of FibroTouch and six serological models in assessing the degree of liver fibrosis among patients with chronic hepatic disease: A single-center retrospective study. PLoS One,2022,17(7):e0270512.
[15] Oka H, Miki K, Kishita I,et al. A multicenter, prospective, randomized, placebo-controlled, double-blind study of a novel pain management device, AT-02, in patients with fibromyalgia. Pain Med,2020,21(2):326-332.
[16] 董丙田, 黄枢, 常建东,等. 声触诊弹性成像与4项血清纤维化指标评估慢性乙型肝炎肝纤维化的效能比较. 中华肝脏病杂志,2020,28(3):269-272.
[17] Hui R, Li Z, Liu Z,et al. The clinical value of color Doppler ultrasonography in measuring the hemodynamics of liver cirrhosis patients' portal and splenic veins. Am J Transl Res,2021 ,13(3):1692-1700.
[18] Northup PG, Garcia-Pagan JC, Garcia-Tsao G,et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases. Hepatology,2021 ,73(1):366-413.
[19] 柳迪, 董鑫, 杨建军,等. 瞬时弹性成像联合门静脉血流动力学指标诊断慢性乙型肝炎患者肝纤维化意义探讨. 实用肝脏病杂志,2020,23(6):797-800.
[20] Saito R, Koizumi N, Nishiyama Y,et al. Evaluation of ultrasonic fibrosis diagnostic system using convolutional network for ordinal regression. Int J Comput Assist Radiol Surg,2021 ,16(11):1969-1975.

应用肝脏硬度检测联合多普勒超声检测门静脉血流动力学指标评估慢性乙型肝炎患者肝纤维化效能研究^*

Concordance between liver biopsy,and the liver stiffness measurement and hemodynamic index combination for the diagnosis of hepatic fibrosis in patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	石莹, 吕永燕, 杨增娣, 刘波, 娄方明, 徐军, 童清平. 超声剪切波弹性成像技术评估CCl₄诱导的肝损伤大鼠肝纤维化程度效能研究[J]. 实用肝脏病杂志, 2023, 26(4): 476-479.
[2]	胡灵溪, 安薪宇, 李妹, 刘百成, 南月敏, 王荣琦. 超声衰减参数诊断体检人群脂肪肝临床应用价值分析^*[J]. 实用肝脏病杂志, 2023, 26(4): 488-491.
[3]	陈丽, 郭明君, 操依含, 曹秀玲, 周静. 瞬时弹性成像检查肝组织硬度诊断酒精性肝硬化效能研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 524-527.
[4]	刘莹, 陈东妙, 王从容. 慢性乙型肝炎、乙型肝炎肝硬化和原发性肝癌患者血清腺苷脱氨酶、α-L-岩藻糖苷酶和AFP-L3水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(4): 552-555.
[5]	周盈营, 赵斌, 信学礼, 刘亚彬. 胆道闭锁小儿肝组织MMP-2和TGF-β1表达及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(4): 588-591.
[6]	贾芳, 尚丰, 宋涛. 良恶性胆囊占位性病变超声表现特征分析^*[J]. 实用肝脏病杂志, 2023, 26(4): 592-595.
[7]	陶贞贞, 王永莉, 孙红艳, 王慧芬. 二维剪切波弹性成像诊断慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 328-331.
[8]	赵景, 何秀波, 谌瑾寰. 肝脏剪切波弹性成像联合GGT/PLT比值诊断慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 332-335.
[9]	张丹蕾, 徐静. 艾米替诺福韦治疗慢性乙型肝炎患者早期疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 336-339.
[10]	郭晓玲, 张耀武, 李梦桃, 张辉. 恩替卡韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 340-343.
[11]	赵玲玲, 王贝贝, 姚勇利, 郑有花, 李亚楠. T2DM合并非酒精性脂肪性肝病伴进展性肝纤维化患者血清抵抗素和TyG指数变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(3): 356-359.
[12]	朱琳, 陈洋, 杨青, 刘俊启. 超声弹性成像评估自身免疫性肝炎患者肝纤维化分期价值分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 360-363.
[13]	孙璀, 曹琳琳, 刘俊. 不同肝病患者血清自身抗体谱阳性率调查^*[J]. 实用肝脏病杂志, 2023, 26(3): 368-371.
[14]	刘玲玉, 王韦, 汤佳美. 超声三维斑点追踪技术早期诊断失代偿期肝硬化患者心肌损害应用价值分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 400-403.
[15]	石磊, 安梓铭, 冯琴. 联合检测血清AFP、AFP-L3%和PIVKA-II水平早期诊断和判断原发性肝癌患者预后临床价值探讨^*[J]. 实用肝脏病杂志, 2023, 26(3): 404-407.